Do You Need a Prescription for ETERNAL Blend? Is It Legal to Buy Online?

Section 503(b) of the Federal Food, Drug, and Cosmetic Act creates prescription-only status: a drug "not safe for use except under the supervision of a practitioner licensed by law to administer such drug" may be dispensed only on a prescription, and dispensing it without one is treated as misbranding. An injectable four-peptide preparation fits that description on its face. The rule attaches to whoever dispenses the drug, not to the person who receives it, which is the structural reason a grey market can exist at all.

A new drug normally needs an approved application before it can be sold. Section 503A of the same Act exempts a drug "compounded for an identified individual patient based on the receipt of a valid prescription order" by a licensed pharmacist from the approval requirement, the manufacturing rules and the full-directions labeling rule. The prescription is not paperwork added to a sale. It is the legal event that makes the sale possible, and it is the reason your name is on the label. The full background is in are peptides legal in the US.

ETERNAL is a brand name for a combination. It does not appear in any journal and it has no file at the FDA. What the FDA reviews is the bulk drug substance a 503A pharmacy compounds from: here GHK-Cu, BPC-157, TB-500 and epithalon (which the FDA spells epitalon). So "is ETERNAL legal" is really four questions, one per component, and the answer for a blend can only be as settled as its least settled component. The longer explanation of the blend itself is in what is ETERNAL Blend.

Category 2 of the FDA's 503A bulk drug substances list is the category for nominated substances flagged as presenting significant safety risks. On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2, effective within seven days, and BPC-157, TB-500, epitalon and injectable GHK-Cu were all among them. The non-injectable form of GHK-Cu, which had sat in Category 1, was removed from that list at the same time.

Removal lifts the safety-risk designation. It does not by itself place a substance on the positive 503A Bulks List; that takes an advisory committee review and a final FDA determination.

On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention in each case, to recommend adding BPC-157 and TB-500, each as the free base and the acetate, to the 503A Bulks List. On 24 July 2026 it voted 7 to 4, with one abstention, to recommend adding epitalon, which had been nominated for insomnia. FDA's own scientists had recommended against inclusion for each, citing insufficient safety, efficacy and characterisation data, and the committee voted the other way.

A committee vote is a recommendation, not a decision. The FDA issues its own determination, and a formal listing goes through notice-and-comment rulemaking. That determination is still pending as of September 2026. Even a final listing would not make any component an FDA-approved drug: the bulks list governs what a pharmacy may compound from. The BPC-157 detail is in is BPC-157 banned.

GHK-Cu was not on the July agenda. The FDA has said the committee will consider it, along with several other April removals, at a meeting before the end of February 2027. Until then it is where the other three were between April and July: no longer flagged, not yet reviewed for the positive list.

None of the four components is restricted today. Three have been recommended for the positive list and await final FDA action; the fourth is scheduled for review. All four remain legal for a physician to prescribe and a state-licensed pharmacy to compound, and none is an FDA-approved drug product. See are peptides FDA approved.